Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
05 Nov 2024
// BUSINESSWIRE
30 Oct 2024
// BUSINESSWIRE
23 Oct 2024
// BUSINESSWIRE
23 Oct 2024
// BUSINESSWIRE
24 Sep 2024
// BUSINESSWIRE
16 Sep 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/sandoz-wins-137m-damages-after-prevailing-years-long-generic-remodulin-dispute-united
Details:
Tyvaso (treprostinil sodium) inhalation solution is an approved prostaglandin agonist. It is under investigation for the treatment of pulmonary arterial hypertension.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tyvaso
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
United Therapeutics Completes Enrollment of TETON 2 Study for Inhaled Treprostinil
Details : Tyvaso (treprostinil sodium) inhalation solution is an approved prostaglandin agonist. It is under investigation for the treatment of pulmonary arterial hypertension.
Brand Name : Tyvaso
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 10, 2024
Details:
The agreement aims for the distribution of Tyvaso (treprostinil inhalation solution), a drug-device combination authorized for the treatment of WHO Group 3 PH-ILD.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tyvaso
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Ferrer Internacional
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 27, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Agreement
Ferrer Obtains the Distribution Rights of a Potential Treatment for IPF and PPF
Details : The agreement aims for the distribution of Tyvaso (treprostinil inhalation solution), a drug-device combination authorized for the treatment of WHO Group 3 PH-ILD.
Brand Name : Tyvaso
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 27, 2024
Details:
The acquisition of Miromatrix will expand United Therapeutics’ platform of organ manufacturing programs and regenerative medicine and upon the achievement of clinical development milestone to Miromatrix’s development-stage, manufactured kidney product known as mirokidney™.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Brand Name: Mirokidney
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: United Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
Details : The acquisition of Miromatrix will expand United Therapeutics’ platform of organ manufacturing programs and regenerative medicine and upon the achievement of clinical development milestone to Miromatrix’s development-stage, manufactured kidney produc...
Brand Name : Mirokidney
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2023
Details:
Tyvaso (treprostinil) inhalation solution is an approved prostacyclin mimetic indicated for the treatment of Pulmonary arterial hypertension. It is under phase 3 clinical development for progressive pulmonary fibrosis.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tyvaso
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tyvaso (treprostinil) inhalation solution is an approved prostacyclin mimetic indicated for the treatment of Pulmonary arterial hypertension. It is under phase 3 clinical development for progressive pulmonary fibrosis.
Brand Name : Tyvaso
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 31, 2023
Details:
The acquisition of Miromatrix will expand United Therapeutics’ platform of organ manufacturing programs and regenerative medicine and upon the achievement of clinical development milestone to Miromatrix’s development-stage, manufactured kidney product known as mirokidney™.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Brand Name: Mirokidney
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: United Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : United Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
United Therapeutics to Acquire Miromatrix Medical
Details : The acquisition of Miromatrix will expand United Therapeutics’ platform of organ manufacturing programs and regenerative medicine and upon the achievement of clinical development milestone to Miromatrix’s development-stage, manufactured kidney produc...
Brand Name : Mirokidney
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 30, 2023
Details:
Through the acquisition, United Therapeutics gains access to Miromatrix’s development-stage, fully-implantable manufactured kidney product known as mirokidney.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Brand Name: Mirokidney
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: United Therapeutics
Deal Size: $91.0 million Upfront Cash: $91.0 million
Deal Type: Acquisition October 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : United Therapeutics
Deal Size : $91.0 million
Deal Type : Acquisition
United Therapeutics to Acquire Miromatrix Medical
Details : Through the acquisition, United Therapeutics gains access to Miromatrix’s development-stage, fully-implantable manufactured kidney product known as mirokidney.
Brand Name : Mirokidney
Molecule Type : Undisclosed
Upfront Cash : $91.0 million
October 30, 2023
Details:
As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system for patients with acute liver failure (ALF) in need of organ support therapies.
Lead Product(s): MiroliverELAP
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MiroliverELAP
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Baxter Healthcare Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2023
Lead Product(s) : MiroliverELAP
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Baxter Healthcare Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system for patients with acute liver failure (ALF) in need of organ support th...
Brand Name : MiroliverELAP
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 01, 2023
Details:
MiroliverELAP is a single-use bioengineered liver which is designed to provide therapeutic support to ALF patients in hopes their native livers will regenerate themselves back to health.
Lead Product(s): MiroliverELAP
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: MiroliverELAP
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Lead Product(s) : MiroliverELAP
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Miromatrix Provides Update on miroliverELAP
Details : MiroliverELAP is a single-use bioengineered liver which is designed to provide therapeutic support to ALF patients in hopes their native livers will regenerate themselves back to health.
Brand Name : MiroliverELAP
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 01, 2023
Details:
The miroliverELAP IND application was submitted in mid-November. The FDA indicated they will provide an official clinical hold letter to Miromatrix within 30 days. Miromatrix plans to provide additional updates pending communication with the FDA.
Lead Product(s): miroliverELAP
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: miroliverELAP
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Lead Product(s) : miroliverELAP
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Miromatrix Announces FDA Clinical Hold on IND Application for miroliverELAP
Details : The miroliverELAP IND application was submitted in mid-November. The FDA indicated they will provide an official clinical hold letter to Miromatrix within 30 days. Miromatrix plans to provide additional updates pending communication with the FDA.
Brand Name : miroliverELAP
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 14, 2022
Details:
Remodulin (treprostinil) is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Remodulin
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Remodulin (treprostinil) is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise.
Brand Name : Remodulin
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 31, 2022
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?